ClinicalTrials.gg
CompletedNCT00098722MOTIVATE 2Updated May 16, 2012Results posted

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

A Phase 2/3 interventional study of Maraviroc (UK-427,857) and optimized background therapy in HIV Infections, sponsored by ViiV Healthcare. Completed at 172 sites in 13 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-05-16.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
474
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.

Enrollment
4th of 44
474 · median 36
Started
2004
the only one that year
Phase 2/3
2 of 44
none open now
Registered
1st of 44
by date
Lead sponsor
8 of 44
ViiV Healthcare

Among the 44 studies testing maraviroc in HIV Infections, this one is the 4th largest by enrollment, is the only one that started in 2004, is one of 2 in phase 2/3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing maraviroc in HIV Infections as a file.
02

Study summary

Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The purpose of this study is to evaluate the antiretroviral activity of maraviroc (UK-427,857) in HIV infected, treatment experienced patients who are failing their current antiretroviral regimen and infected with R5-tropic virus exclusively. This study will involve more than 100 centers in Europe and Australia to achieve a total randomized subject population of 500 subjects. Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment. This may be extended for an additional year depending on the results at 48 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40 and 48. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 24 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will also be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24 and 48.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)
  • -1 RNA viral load of greater than or equal to 5,000 copies/mL
  • Stable pre-study antiretroviral regimen, or on no antiretroviral agents, for at least 4 weeks
  • Documented genotypic or phenotypic resistance to three of the four antiretroviral drug classes, OR, Antiretroviral-class experience greater than or equal to 6 months (sequential or cumulative) with at least three of the following: One nucleoside or nucleotide reverse transcriptase inhibitor, one non-nucleoside reverse transcriptase inhibitor, two protease inhibitors (excluding low-dose ritonavir) and/or enfuvirtide
  • Be willing to remain on randomized treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure
  • A negative urine pregnancy test at the baseline visit for Women of Child Bearing Potential ()
  • Effective barrier for WOCBP and males

Exclusion criteria

Exclusion Criteria:

  • Patients requiring treatment with more than 6 antiretroviral agents (excluding low-dose ritonavir)
  • Prior treatment with maraviroc (UK-427,857) or another experimental entry inhibitor for more than 14 days
  • Suspected or documented active, untreated HIV-1 related opportunistic infection (OI) or other condition requiring acute therapy
  • Treatment for an active opportunistic infection, or unexplained temperature >38.5 degrees Celsius for 7 consecutive days
  • Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up
  • Lactating women, or planned pregnancy during the trial period
  • Significant renal insufficiency
  • Initiating therapy with a potentially myelosuppressive, neurotoxic, hepatotoxic and/or cytotoxic agent within 60 days prior to randomization or the expected need for such therapy during the study period
  • Documented or suspected acute hepatitis or pancreatitis within 30 days prior to randomization
  • Significantly elevated liver enzymes or cirrhosis
  • Significant neutropenia, anemia or thrombocytopenia
  • Malabsorption or an inability to tolerate oral medications
  • Certain medications
  • requiring parenteral chemotherapy that must be continued for the duration of the trial
  • X4- or dual/mixed-tropic virus or repeated assay failure
  • Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
474 participants (actual)

Study arms

  • Experimental
    1

    Drug: Maraviroc (UK-427,857) · Drug: optimized background therapy

  • Placebo comparator
    2

    Drug: Maraviroc (UK-427,857) · Drug: optimized background therapy

  • Experimental
    3

    Drug: optimized background therapy

Interventions

  • maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.

  • \[OBT (3-6 drugs based on treatment history and resistance testing)\]

    Also known as: Selzentry

  • maraviroc (UK-427,857) 150 mg taken twice daily

    Also known as: Selzentry

  • Drugoptimized background therapy

    \[OBT (3-6 drugs based on treatment history and resistance testing)\]

  • Drugoptimized background therapy

    \[OBT (3-6 drugs based on treatment history and resistance testing)\]

06

What researchers measure

Primary outcomes

  1. Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline

    Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

    Time frame: Baseline

  2. Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24

    Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48

    Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

    Time frame: Baseline and Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL

    Time frame: Week 24 and 48

  2. Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 0.5 log10 Decrease From Baseline

    Time frame: Week 24 and 48

  3. Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 1.0 log10 Decrease From Baseline

    Time frame: Week 24 and 48

  4. Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL

    Time frame: Week 24 and 48

  5. Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline

    Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

    Time frame: Baseline

  6. Change From Baseline in CD4 Cell Count at Week 24 and 48

    Change from baseline in CD4 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

    Time frame: Week 24 and 48

  7. Change From Baseline in CD8 Cell Count at Week 24 and 48

    Change from baseline in CD8 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

    Time frame: Week 24 and 48

  8. Time to Virological Failure

    Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up\[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL (2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL (2 consecutive visits);failure if level \>=400 copies/mL (2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.

    Time frame: Week 48

  9. Time-Averaged Difference (TAD) From Baseline in log10 Transformed HIV-1 RNA Levels

    TAD from baseline was calculated as area under the curve of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as the average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

    Time frame: Baseline to Week 24 and Week 48

  10. Number of Participants With Genotypic Susceptibility Score (GSS) and Phenotypic Susceptibility Score (PSS) at Screening

    Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to protease inhibitors(PIs), nucleoside reverse transcriptase inhibitors(NRTIs) and non-nucleoside reverse transcriptase inhibitors(NNRTIs) were evaluated at screening (not at baseline), by Monogram Biosciences PhenoSense genotyping (GT) assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

    Time frame: Screening

  11. Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24

    Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 24 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

    Time frame: Screening and time of failure through Week 24

  12. Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 48

    Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 48 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

    Time frame: Screening and time of failure through Week 48

  13. Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24

    Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/Mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 24 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as the last on treatment assessment.

    Time frame: Baseline and time of failure through Week 24

  14. Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48

    Number of participants per tropism status R5, X4, DM, or NR/NP at baseline and time of failure analyzed through week 48 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as BLQ. The assessment for time of treatment failure was defined as the last on treatment assessment.

    Time frame: Baseline and time of failure through Week 48

  15. Change From Baseline in Viral Load at Week 24 and Week 48 by Overall Susceptibility Score (OSS) at Screening

    Association between baseline resistance and virological response was assessed as change in viral load by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility. Baseline value is the average of the values from screening, randomization and immediately pre-dose.

    Time frame: Baseline, Week 24 and Week 48

07

Results

Posted May 16, 2012

Participant flow

Double Blind Phase
Participant flow — Double Blind Phase
MilestoneMaraviroc QD, Double BlindMaraviroc BID, Double BlindPlacebo, Double BlindMaraviroc BID, Open LabelIn Study-off Drug (ISOD), Open LabelMaraviroc BID, Observation PhaseIn Study-off Drug (ISOD), Observation Phase
Started186194940000
Treated182191910000
Completed0000000
Not completed186194940000
Withdrew: Adverse event7730000
Withdrew: Death2500000
Withdrew: Lack of efficacy2123150000
Withdrew: Participant defaulted161190000
Withdrew: Pregnancy1000000
Withdrew: Randomized, not treated4330000
Withdrew: Ongoing at cut-off date128137570000
Withdrew: Other7870000
Open Label Phase
Participant flow — Open Label Phase
MilestoneMaraviroc QD, Double BlindMaraviroc BID, Double BlindPlacebo, Double BlindMaraviroc BID, Open LabelIn Study-off Drug (ISOD), Open LabelMaraviroc BID, Observation PhaseIn Study-off Drug (ISOD), Observation Phase
Started0002725000
Completed0000000
Not completed0002725000
Withdrew: Adverse event0005000
Withdrew: Death0002000
Withdrew: Lack of efficacy0008000
Withdrew: Pregnancy0001000
Withdrew: Participant defaulted00018000
Withdrew: Ongoing at cut-off date0002205000
Withdrew: Other00018000
Observation Phase
Participant flow — Observation Phase
MilestoneMaraviroc QD, Double BlindMaraviroc BID, Double BlindPlacebo, Double BlindMaraviroc BID, Open LabelIn Study-off Drug (ISOD), Open LabelMaraviroc BID, Observation PhaseIn Study-off Drug (ISOD), Observation Phase
Started0000020565
Completed0000016048
Not completed000004517
Withdrew: Death0000053
Withdrew: Lack of efficacy0000020
Withdrew: Participant defaulted00000174
Withdrew: Other000002110

Outcome measures

PrimaryLog 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline

Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

Time frame:
Baseline
Reported as:
Mean · log10 copies/milliliter(log10 copies/mL)
Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline
log10 copies/milliliter(log10 copies/mL)Maraviroc QDMaraviroc BIDPlacebo
Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline4.873 ± 0.66414.840 ± 0.62054.886 ± 0.6957
PrimaryChange From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24

Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24
log10 copies/mLMaraviroc QDMaraviroc BIDPlacebo
Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24-1.950 ± 0.1054-1.971 ± 0.1026-0.929 ± 0.1473
Statistical analysis
  • Maraviroc QD vs Placebo · Ls mean difference: -1.021 · 97.5% CI -1.426 to -0.616
  • Maraviroc BID vs Placebo · Ls mean difference: -1.042 · 97.5% CI -1.444 to -0.640
PrimaryChange From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48

Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

Time frame:
Baseline and Week 48
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48
log10 copies/mLMaraviroc QDMaraviroc BIDPlacebo
Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48-1.718 ± 0.1086-1.865 ± 0.1057-0.757 ± 0.1518
Statistical analysis
  • Maraviroc QD vs Placebo · Ls mean difference: -0.961 · 97.5% CI -1.379 to -0.544
  • Maraviroc BID vs Placebo · Ls mean difference: -1.109 · 97.5% CI -1.523 to -0.695
SecondaryPercentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL
Time frame:
Week 24 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL
percentage of participantsMaraviroc QDMaraviroc BIDPlacebo
Week 2455.4961.2623.08
Week 4852.7554.9723.08
Statistical analysis
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.59 · 95% CI 2.56 to 8.23
  • Maraviroc BID vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 6.01 · 95% CI 3.35 to 10.78
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.03 · 95% CI 2.25 to 7.20
  • Maraviroc BID vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.41 · 95% CI 2.47 to 7.85
SecondaryPercentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 0.5 log10 Decrease From Baseline
Time frame:
Week 24 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 0.5 log10 Decrease From Baseline
percentage of participantsMaraviroc QDMaraviroc BIDPlacebo
Week 2469.7872.2537.36
Week 4860.9965.9731.87
Statistical analysis
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.69 · 95% CI 2.72 to 8.10
  • Maraviroc BID vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.01 · 95% CI 2.91 to 8.62
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.67 · 95% CI 2.13 to 6.32
  • Maraviroc BID vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.64 · 95% CI 2.69 to 8.02
SecondaryPercentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 1.0 log10 Decrease From Baseline
Time frame:
Week 24 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 1.0 log10 Decrease From Baseline
percentage of participantsMaraviroc QDMaraviroc BIDPlacebo
Week 2466.4869.6330.77
Week 4858.7963.3527.47
Statistical analysis
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.58 · 95% CI 2.64 to 7.92
  • Maraviroc BID vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.42 · 95% CI 3.13 to 9.39
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.01 · 95% CI 2.29 to 7.00
  • Maraviroc BID vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.08 · 95% CI 2.91 to 8.89
SecondaryPercentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
Time frame:
Week 24 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
percentage of participantsMaraviroc QDMaraviroc BIDPlacebo
Week 2445.6040.8420.88
Week 4845.0544.5017.58
Statistical analysis
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.55 · 95% CI 1.95 to 6.48
  • Maraviroc BID vs Placebo · Regression, Logistic · p = 0.0005 · Odds ratio (or): 2.88 · 95% CI 1.59 to 5.23
  • Maraviroc QD vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.23 · 95% CI 2.26 to 7.92
  • Maraviroc BID vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.10 · 95% CI 2.20 to 7.64
SecondaryCluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline

Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

Time frame:
Baseline
Reported as:
Mean · cells per microliter (cells/μL)
Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline
cells per microliter (cells/μL)Maraviroc QDMaraviroc BIDPlacebo
CD4206.0 ± 171.99204.9 ± 149.21198.5 ± 140.39
CD8994.6 ± 658.03996.9 ± 576.97952.3 ± 598.19
SecondaryChange From Baseline in CD4 Cell Count at Week 24 and 48

Change from baseline in CD4 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

Time frame:
Week 24 and 48
Reported as:
Least squares mean · cells/μL
Change From Baseline in CD4 Cell Count at Week 24 and 48
cells/μLMaraviroc QDMaraviroc BIDPlacebo
Week 24111.72 ± 7.821101.89 ± 7.68463.78 ± 10.929
Week 48121.49 ± 8.651127.80 ± 8.49969.34 ± 12.088
Statistical analysis
  • Maraviroc QD vs Placebo · Ls mean difference: 47.94 · 95% CI 21.64 to 74.25
  • Maraviroc BID vs Placebo · Ls mean difference: 38.12 · 95% CI 11.96 to 64.28
  • Maraviroc QD vs Placebo · Ls mean difference: 52.15 · 95% CI 23.06 to 81.25
  • Maraviroc BID vs Placebo · Ls mean difference: 58.46 · 95% CI 29.53 to 87.40
SecondaryChange From Baseline in CD8 Cell Count at Week 24 and 48

Change from baseline in CD8 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

Time frame:
Week 24 and 48
Reported as:
Least squares mean · cells/μL
Change From Baseline in CD8 Cell Count at Week 24 and 48
cells/μLMaraviroc QDMaraviroc BIDPlacebo
Week 24340.74 ± 41.601255.40 ± 40.873122.18 ± 58.150
Week 48241.43 ± 33.789244.75 ± 33.198104.51 ± 47.231
Statistical analysis
  • Maraviroc QD vs Placebo · Ls mean difference: 218.57 · 95% CI 78.59 to 358.54
  • Maraviroc BID vs Placebo · Ls mean difference: 133.22 · 95% CI -6.03 to 272.47
  • Maraviroc QD vs Placebo · Ls mean difference: 136.93 · 95% CI 23.24 to 250.62
  • Maraviroc BID vs Placebo · Ls mean difference: 140.25 · 95% CI 27.15 to 253.35
SecondaryTime to Virological Failure

Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up\[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL (2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL (2 consecutive visits);failure if level \>=400 copies/mL (2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.

Time frame:
Week 48
Reported as:
Median · days
Time to Virological Failure
daysMaraviroc QDMaraviroc BIDPlacebo
Time to Virological Failure345.00 (197.00 to NA)361.00 (361.00 to NA)0.00 (NA to NA)
Statistical analysis
  • Maraviroc QD vs Placebo · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.40 · 95% CI 0.29 to 0.56
  • Maraviroc BID vs Placebo · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.33 · 95% CI 0.23 to 0.46
SecondaryTime-Averaged Difference (TAD) From Baseline in log10 Transformed HIV-1 RNA Levels

TAD from baseline was calculated as area under the curve of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as the average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

Time frame:
Baseline to Week 24 and Week 48
Reported as:
Least squares mean · log10 copies/mL
Time-Averaged Difference (TAD) From Baseline in log10 Transformed HIV-1 RNA Levels
log10 copies/mLMaraviroc QDMaraviroc BIDPlacebo
Week 24-1.748 ± 0.0897-1.755 ± 0.0873-0.872 ± 0.1254
Week 48-1.603 ± 0.0994-1.781 ± 0.0968-0.748 ± 0.1390
Statistical analysis
  • Maraviroc QD vs Placebo · Ls mean difference: -0.876 · 95% CI -1.177 to -0.575
  • Maraviroc BID vs Placebo · Ls mean difference: -0.882 · 95% CI -1.181 to -0.584
  • Maraviroc QD vs Placebo · Ls mean difference: -0.855 · 95% CI -1.189 to -0.521
  • Maraviroc BID vs Placebo · Ls mean difference: -1.033 · 95% CI -1.364 to -0.701
SecondaryNumber of Participants With Genotypic Susceptibility Score (GSS) and Phenotypic Susceptibility Score (PSS) at Screening

Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to protease inhibitors(PIs), nucleoside reverse transcriptase inhibitors(NRTIs) and non-nucleoside reverse transcriptase inhibitors(NNRTIs) were evaluated at screening (not at baseline), by Monogram Biosciences PhenoSense genotyping (GT) assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

Time frame:
Screening
Reported as:
Number · participants
Number of Participants With Genotypic Susceptibility Score (GSS) and Phenotypic Susceptibility Score (PSS) at Screening
participantsMaraviroc QDMaraviroc BIDPlacebo
GSS: 0394320
GSS: 1645824
GSS: 2253220
GSS: greater than or equal to 3525725
GSS: missing212
PSS: 0202612
PSS: 1464220
PSS: 2423823
PSS: greater than or equal to 3718434
PSS: missing312
SecondaryNumber of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24

Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 24 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

Time frame:
Screening and time of failure through Week 24
Reported as:
Number · participants
Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24
participantsMaraviroc QDMaraviroc BIDPlacebo
Change in GSS by less than -3 (n= 22, 25, 40)010
Change in GSS by -3 (n= 22, 25, 40)000
Change in GSS by -2 (n= 22, 25, 40)001
Change in GSS by -1 (n= 22, 25, 40)9615
Change in GSS by 0 (n= 22, 25, 40)131522
Change in GSS by 1 (n= 22, 25, 40)031
Change in GSS by 2 (n= 22, 25, 40)001
Change in GSS by 3 (n= 22, 25, 40)000
Change in GSS by greater than 3 (n= 22, 25, 40)000
Change in PSS by less than -3 (n= 22, 24, 40)000
Change in PSS by -3 (n= 22, 24, 40)102
Change in PSS by -2 (n= 22, 24, 40)233
Change in PSS by -1 (n= 22, 24, 40)8816
Change in PSS by 0 (n= 22, 24, 40)101318
Change in PSS by 1 (n= 22, 24, 40)101
Change in PSS by 2 (n= 22, 24, 40)000
Change in PSS by 3 (n= 22, 24, 40)000
Change in PSS by greater than 3 (n= 22, 24, 40)000
SecondaryNumber of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 48

Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 48 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to \>3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

Time frame:
Screening and time of failure through Week 48
Reported as:
Number · participants
Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 48
participantsMaraviroc QDMaraviroc BIDPlacebo
Change in GSS by less than -3 (n= 35, 33, 46)010
Change in GSS by -3 (n= 35, 33, 46)000
Change in GSS by -2 (n= 35, 33, 46)002
Change in GSS by -1 (n= 35, 33, 46)12617
Change in GSS by 0 (n= 35, 33, 46)232224
Change in GSS by 1 (n= 35, 33, 46)042
Change in GSS by 2 (n= 35, 33, 46)001
Change in GSS by 3 (n= 35, 33, 46)000
Change in GSS by greater than 3 (n= 35, 33, 46)000
Change in PSS by less than -3 (n= 35, 32, 46)000
Change in PSS by -3 (n= 35, 32, 46)103
Change in PSS by -2 (n= 35, 32, 46)334
Change in PSS by -1 (n= 35, 32, 46)13918
Change in PSS by 0 (n= 35, 32, 46)161919
Change in PSS by 1 (n= 35, 32, 46)202
Change in PSS by 2 (n= 35, 32, 46)010
Change in PSS by 3 (n= 35, 32, 46)000
Change in PSS by greater than 3 (n= 35, 32, 46)000
SecondaryNumber of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24

Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/Mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 24 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as the last on treatment assessment.

Time frame:
Baseline and time of failure through Week 24
Reported as:
Number · participants
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24
participantsMaraviroc QDMaraviroc BIDPlacebo
Baseline: R5; Treatment failure: R58736
Baseline: R5; Treatment failure: X4220
Baseline: R5; Treatment failure: DM563
Baseline: R5; Treatment failure: NR/NP652
Baseline: DM; Treatment failure: R5102
Baseline: DM; Treatment failure: X4020
Baseline: DM; Treatment failure: DM370
Baseline: DM; Treatment failure: NR/NP010
SecondaryNumber of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48

Number of participants per tropism status R5, X4, DM, or NR/NP at baseline and time of failure analyzed through week 48 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load \<500 copies/ml categorized as BLQ. The assessment for time of treatment failure was defined as the last on treatment assessment.

Time frame:
Baseline and time of failure through Week 48
Reported as:
Number · participants
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
participantsMaraviroc QDMaraviroc BIDPlacebo
Baseline: R5; Treatment failure: R517940
Baseline: R5; Treatment failure: X4220
Baseline: R5; Treatment failure: DM8103
Baseline: R5; Treatment failure: NR/NP662
Baseline: DM; Treatment failure: R5103
Baseline: DM; Treatment failure: X4020
Baseline: DM; Treatment failure: DM370
Baseline: DM; Treatment failure: NR/NP010
SecondaryChange From Baseline in Viral Load at Week 24 and Week 48 by Overall Susceptibility Score (OSS) at Screening

Association between baseline resistance and virological response was assessed as change in viral load by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility. Baseline value is the average of the values from screening, randomization and immediately pre-dose.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · log10copies/mL
Change From Baseline in Viral Load at Week 24 and Week 48 by Overall Susceptibility Score (OSS) at Screening
log10copies/mLMaraviroc QDMaraviroc BIDPlacebo
Week 24; Screening OSS 0 (n= 22, 29, 16)-1.721 ± 1.0477-1.231 ± 1.2924-0.264 ± 0.8979
Week 24; Screening OSS 1 (n= 54, 48, 23)-1.822 ± 1.0244-2.051 ± 1.1860-0.651 ± 0.9756
Week 24; Screening OSS 2 (n= 37, 39, 21)-2.145 ± 1.4052-2.515 ± 0.8209-0.611 ± 0.9732
Week 24; Screening OSS >=3 (n= 64, 68, 29)-2.655 ± 1.1364-2.530 ± 1.2694-2.109 ± 1.3495
Week 24; Screening OSS= Missing (n= 3, 1, 2)-2.642 ± 0.9282-0.544 ± NA-1.169 ± 2.1350
Week 48; Screening OSS 0 (n= 22, 29, 16)-1.745 ± 1.2354-1.290 ± 1.2978-0.249 ± 0.8727
Week 48; Screening OSS 1 (n= 54, 48, 23)-1.678 ± 1.2115-1.899 ± 1.1966-0.594 ± 0.9454
Week 48; Screening OSS 2 (n= 38, 39, 21)-2.207 ± 1.3866-2.565 ± 0.8734-0.591 ± 0.9309
Week 48; Screening OSS >=3 (n= 63, 68, 29)-2.448 ± 1.2477-2.426 ± 1.2977-1.942 ± 1.4167
Week 48; Screening OSS= Missing (n= 3, 1, 2)-2.795 ± 0.5079-0.833 ± NA-1.105 ± 2.0447

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maraviroc QD—40/182 (22%)138/182 (75.8%)
Maraviroc BID—46/191 (24.1%)147/191 (77%)
Placebo—16/91 (17.6%)64/91 (70.3%)
Maraviroc BID, Open Label—28/272 (10.3%)15/272 (5.5%)
In Study-off Drug, Open Label—0/50 (0%)0/50 (0%)
Maraviroc BID, Observation Phase—0/205 (0%)0/205 (0%)
In Study-off Drug, Observation Phase—0/65 (0%)0/65 (0%)
Most frequent serious events
Showing 10 of 153
Most frequent serious events
EventMaraviroc QDMaraviroc BIDPlaceboMaraviroc BID, Open LabelIn Study-off Drug, Open LabelMaraviroc BID, Observation PhaseIn Study-off Drug, Observation Phase
PyrexiaGeneral disorders1/1822/1913/911/2720/500/2050/65
PneumoniaInfections and infestations2/1825/1911/913/2720/500/2050/65
VomitingGastrointestinal disorders3/1823/1912/910/2720/500/2050/65
Renal failure acuteRenal and urinary disorders1/1821/1912/910/2720/500/2050/65
NauseaGastrointestinal disorders3/1822/1911/910/2720/500/2050/65
Aortic valve diseaseCardiac disorders0/1820/1911/910/2720/500/2050/65
Supraventricular tachyarrhythmiaCardiac disorders0/1820/1911/910/2720/500/2050/65
DiarrhoeaGastrointestinal disorders2/1822/1911/911/2720/500/2050/65
Drug hypersensitivityImmune system disorders1/1821/1911/910/2720/500/2050/65
Anogenital wartsInfections and infestations2/1820/1910/910/2720/500/2050/65
Most frequent other events
Showing 10 of 30
Most frequent other events
EventMaraviroc QDMaraviroc BIDPlaceboMaraviroc BID, Open LabelIn Study-off Drug, Open LabelMaraviroc BID, Observation PhaseIn Study-off Drug, Observation Phase
DiarrhoeaGastrointestinal disorders49/18239/19119/9115/2720/500/2050/65
NauseaGastrointestinal disorders39/18233/19117/910/2720/500/2050/65
HeadacheNervous system disorders36/18230/19116/910/2720/500/2050/65
NasopharyngitisInfections and infestations28/18227/1914/910/2720/500/2050/65
CoughRespiratory, thoracic and mediastinal disorders17/18228/1915/910/2720/500/2050/65
FatigueGeneral disorders25/18222/19113/910/2720/500/2050/65
PyrexiaGeneral disorders14/18226/1918/910/2720/500/2050/65
Upper respiratory tract infectionInfections and infestations20/18226/1915/910/2720/500/2050/65
VomitingGastrointestinal disorders24/18220/1919/910/2720/500/2050/65
BronchitisInfections and infestations18/18218/1917/910/2720/500/2050/65

Baseline characteristics

Age, Customized
Age, Customized(participants)Maraviroc QDMaraviroc BIDPlaceboTotal
Less than 18 years1001
18 to 24 years1102
25 to 34 years89623
35 to 44 years857140196
45 to 54 years637032165
55 to 64 years19371167
Greater than or equal to 65 years53210
Sex: Female, Male
Sex: Female, Male(Participants)Maraviroc QDMaraviroc BIDPlaceboTotal
Female29211262
Male15317079402
08

Study locations

172 sites
  • Pfizer Investigational Site
    Hobson City, Alabama 36201, United States
  • Pfizer Investigational Site
    Garden Grove, California 92845, United States
  • Pfizer Investigational Site
    Los Angeles, California 90036, United States
  • Pfizer Investigational Site
    Oakland, California 94609-3480, United States
  • Pfizer Investigational Site
    Palm Springs, California 92262, United States
  • Pfizer Investigational Site
    Tarzana, California 91356, United States
  • Pfizer Investigational Site
    Norwalk, Connecticut 06851, United States
  • Pfizer Investigational Site
    Southport, Connecticut 06490, United States
  • Pfizer Investigational Site
    Stratford, Connecticut 06614, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20007, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20010-2976, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33765, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021-6327, United States
  • Pfizer Investigational Site
    Miami Beach, Florida 33139, United States
  • Pfizer Investigational Site
    Miami, Florida 33137, United States
  • Pfizer Investigational Site
    Miami, Florida 33145, United States
  • Pfizer Investigational Site
    Miami, Florida 33155, United States
  • Pfizer Investigational Site
    Pensacola, Florida 32504, United States
  • Pfizer Investigational Site
    Safety Harbor, Florida 34695, United States
  • Pfizer Investigational Site
    St. Petersburg, Florida 33713, United States
  • Pfizer Investigational Site
    Tampa, Florida 33611, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30309, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30318-2513, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30339-3915, United States
  • Pfizer Investigational Site
    Jonesboro, Georgia 30236, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60613, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60657, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62702, United States
  • Pfizer Investigational Site
    Metairie, Louisiana 70006, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21201, United States
  • Pfizer Investigational Site
    Silver Spring, Maryland 20910, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109-0008, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109-0352, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48201, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64106, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63139-2909, United States
  • Pfizer Investigational Site
    Buffalo, New York 14215, United States
  • Pfizer Investigational Site
    East Meadow, New York 11554, United States
  • Pfizer Investigational Site
    Elmira, New York 14905, United States
  • Pfizer Investigational Site
    New York, New York 10011, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    New York, New York 10025, United States
  • Pfizer Investigational Site
    New York, New York 10029, United States
  • Pfizer Investigational Site
    Greenville, North Carolina 27834, United States
  • Pfizer Investigational Site
    Akron, Ohio 44304, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44109, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74135, United States
  • Pfizer Investigational Site
    Portland, Oregon 97210, United States
  • Pfizer Investigational Site
    Portland, Oregon 97227, United States
  • Pfizer Investigational Site
    West Reading, Pennsylvania 19611, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29403, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29425, United States
  • Pfizer Investigational Site
    Dallas, Texas 75219, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76104, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76107, United States
  • Pfizer Investigational Site
    Pasadena, Texas 77505-4245, United States
  • Pfizer Investigational Site
    Danville, Virginia 24541, United States
  • Pfizer Investigational Site
    Hampton, Virginia 23666, United States
  • Pfizer Investigational Site
    Lynchburg, Virginia 24501, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23298, United States
  • Pfizer Investigational Site
    Burwood, New South Wales 2134, Australia
  • Pfizer Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Surry Hills, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Sydney, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Wentworthville, New South Wales 2145, Australia
  • Pfizer Investigational Site
    Herston, Queensland 4029, Australia
  • Pfizer Investigational Site
    Miami, Queensland 4220, Australia
  • Pfizer Investigational Site
    Melbourne, Victoria 3004, Australia
  • Pfizer Investigational Site
    North Fitzroy, Victoria 3068, Australia
  • Pfizer Investigational Site
    South Yarra, Victoria 3141, Australia
  • Pfizer Investigational Site
    Darlinghurst, 2010, Australia
  • Pfizer Investigational Site
    Brussels, 1000, Belgium
  • Pfizer Investigational Site
    Brussels, 1070, Belgium
  • Pfizer Investigational Site
    Brussels, 1200, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Liege, 4000, Belgium
  • Pfizer Investigational Site
    Montreal, Quebec H2L 2W5, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • Pfizer Investigational Site
    Toulon, Bp1412 83056, France
  • Pfizer Investigational Site
    Lyon, Cedex 02 69288, France
  • Pfizer Investigational Site
    Orleans, Cedex 02 45067, France
  • Pfizer Investigational Site
    Marseille, Cedex 09 13274, France
  • Pfizer Investigational Site
    Paris, Cedex 10 75475, France
  • Pfizer Investigational Site
    Paris, Cedex 12 75571, France
  • Pfizer Investigational Site
    Bobigny, Cedex 93009, France
  • Pfizer Investigational Site
    Caen, Cedex 14033, France
  • Pfizer Investigational Site
    Le Kremlin Bicêtre, 94270, France
  • Pfizer Investigational Site
    Montpellier, 34295, France
  • Pfizer Investigational Site
    Nantes, 44093, France
  • Pfizer Investigational Site
    Nice Cedex 3, 06, 06202, France
  • Pfizer Investigational Site
    Paris, 75, 75020, France
  • Pfizer Investigational Site
    Paris, 75015, France
  • Pfizer Investigational Site
    Paris, 75018, France
  • Pfizer Investigational Site
    Aachen, 52062, Germany
  • Pfizer Investigational Site
    Berlin, 12157, Germany
  • Pfizer Investigational Site
    Bochum, 44791, Germany
  • Pfizer Investigational Site
    Bonn, 53105, Germany
  • Pfizer Investigational Site
    Duesseldorf, 40225, Germany

Showing the first 100 of 172 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lewis ME, Simpson P, Mori J, Jubb B, Sullivan J, McFadyen L, van der Ryst E, Craig C, Robertson DL, Westby M. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens. Antivir Chem Chemother. 2021 Jan-Dec;29:20402066211030380. doi: 10.1177/20402066211030380. PubMed 34343443 ↗
  • Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):78-81. doi: 10.1097/QAI.0b013e3182a7a97a. PubMed 24419064 ↗
  • Hardy WD, Gulick RM, Mayer H, Fatkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558-64. doi: 10.1097/QAI.0b013e3181ee3d82. PubMed 20703158 ↗
  • Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. PubMed 18832245 ↗
  • Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152. PubMed 18832244 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Apr 2007 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2004
First posted
Dec 8, 2004
Start
Dec 2004
Primary completionActual
Apr 2007
CompletionActual
Apr 2011
Results first posted
May 16, 2012
Last update
May 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00098722
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 8, 2004
Start date
Dec 2004
Primary completion
Apr 2007
Completion
Apr 2011
Results posted
May 16, 2012
Last update
May 16, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion